Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Rhea-AI Summary

Lipella Pharmaceuticals (NASDAQ: LIPO) has secured U.S. Patent No. 12,326,492 for its diagnostic technology focused on detecting interstitial cystitis through MRI imaging. The patent, issued on June 10, 2025, provides protection until at least 2045 and covers methods for detecting lesions in body cavities using MRI. The technology has potential applications in monitoring mucosal disorders, including the company's existing development programs: LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis, and LP-50 for bladder cancer. The non-invasive monitoring capability using novel MRI contrast agents could enhance clinical development efforts and serve as an early detection tool.

Positive

• Patent protection secured until at least 2045 for diagnostic technology
• Technology can enhance monitoring of multiple development programs including LP-310, LP-10, and LP-50
• Non-invasive monitoring capability could serve as an early detection tool
• Strengthens company's strategic position in drug delivery

Negative

• None.

PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial Cystitis.” The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions.

The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enhanced outcome assessments to our development programs; especially mucosal disorders, including our existing programs: LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis and LP-50 for bladder cancer." said Dr. Michael Chancellor, Chief Medical Officer.

“This patent strengthens Lipella’s strategic position in drug delivery,” said Jonathan Kaufman, Chief Executive Officer. "The ability to non-invasively monitor the progression (or regression) of body cavity lesions, using a novel MRI contrast agent, will not only enhance our existing clinical development efforts, but can itself become a clinically-relevant early detection tool.”

About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn.

Forward-Looking Statements
This press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, including the statistically significant safety and efficacy data presented above for LP-310, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the current clinical trial for LP-310, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.

CONTACT:
Jonathan Kaufman
Chief Executive Officer
Lipella Pharmaceuticals Inc.
Info@Lipella.com
1-412-894-1853

PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com

FAQ

What is the new patent issued to Lipella Pharmaceuticals (LIPO)?

Lipella received U.S. Patent No. 12,326,492 for Systems and Methods of Detecting Interstitial Cystitis, which covers MRI-based methods for detecting lesions in body cavities.

How long will Lipella's new diagnostic patent protection last?

The patent provides protection through at least 2045, with potential for extensions.

What are the potential applications of Lipella's new MRI diagnostic technology?

The technology can monitor mucosal disorders including oral lichen planus, hemorrhagic cystitis, and bladder cancer through their programs LP-310, LP-10, and LP-50 respectively.

How does Lipella's new patented diagnostic technology work?

The technology uses magnetic resonance imaging (MRI) with a novel contrast agent to non-invasively detect and monitor lesions or permeability defects in body cavities.

What development programs could benefit from Lipella's new diagnostic patent?

The technology can enhance outcome assessments for LP-310 (oral lichen planus), LP-10 (hemorrhagic cystitis), and LP-50 (bladder cancer) programs.